UNSPSC 51141561: Ezogabine or retigabine

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 12G01I6BBU. European Medicines Agency schedules Retigabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10291MIG. Ezogabine generally arises in the molecular formula C16H18FN3O2. The term 'ezogabine' is a European Medicines Agency European Public Assessment Report System designation. Ezogabine or retigabine bears US NLM identifiers UMLS ID C0530684 and NCI Concept Code C72839.

SMILES: FC1CCC(CNC2CC(N)C(NC(=O)OCC)CC2)CC1.

UNSPSC 51141561 Ezogabine or retigabine (Commodity) shows minimal alignment with recent state and local procurement activity. The code nominally covers a specific antiepileptic pharmaceutical compound, but the only recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone (an opioid antagonist) and drug deactivation systems, neither of which falls within the scope of ezogabine or retigabine procurement. The mismatch suggests either a tagging error in the county's e-procurement system or that this code is not actively used for actual pharmaceutical procurement at the state and local level.

Seminole County issued the IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2023. The procurement includes standard state and local compliance requirements—drug-free workplace certification, E-Verify, commercial general liability and workers' compensation insurance, and potential FEMA funding with attendant federal regulatory adherence (Clean Air Act and Federal Water Pollution Control Act). Beyond this single misaligned opportunity, the code shows no recent activity relevant to ezogabine or retigabine procurement among state and local buyers.